Brainomix Secures £14M Series C Funding to Enhance AI Imaging Technology in Healthcare

Brainomix's Illustrious Journey: Pioneering AI in Healthcare

Brainomix, a groundbreaking company hailing from the University of Oxford, has revolutionized healthcare through its innovative AI-powered imaging solutions. The recent completion of a £14 million ($18 million) Series C investment round underscores the firm’s commitment to advancing its life-saving technologies in diagnosing and treating stroke and lung fibrosis.

The funding, co-led by prominent healthtech investors, including Parkwalk Advisors and the Boehringer Ingelheim Venture Fund, marks a significant milestone in Brainomix's ongoing journey. This injection of capital will substantially bolster the company's ambitions, particularly its expansion into the U.S. market, where it has already secured vital FDA clearances for its technology.

Major Accomplishments in Stroke Treatment

Brainomix has made notable strides with its flagship product, Brainomix 360 Stroke. This cutting-edge AI platform automates the use of validated imaging biomarkers, enabling healthcare providers to enhance their diagnostic and treatment capabilities. Impressively, this technology has been utilized in over 300 hospitals across Europe, benefitting more than 1.5 million patients and demonstrating a significant improvement in treatment rates. Research has shown that hospitals employing Brainomix 360 Stroke observed a remarkable 50% increase in mechanical thrombectomy procedures, a critical intervention that reduces disability from stroke.

The completion of the Series C round equips Brainomix with the necessary resources to escalate its commercial efforts in the U.S. market. The firm is keen to establish a robust presence there, capitalizing on its successful innovations in stroke care.

Expanding into Lung Fibrosis Technologies

In addition to stroke treatment, Brainomix is also focusing on lung fibrosis. Its Brainomix 360 e-Lung technology, which recently achieved FDA clearance, aims to accurately predict the disease's progression. The company partners with Boehringer Ingelheim, the leader in lung fibrosis treatments, to evaluate the real-world effects of e-Lung in facilitating timely diagnoses and improving access to essential treatments for progressive lung fibrosis.

Dr. Michalis Papadakis, CEO and Co-Founder at Brainomix, expressed gratitude toward all investors for their support and emphasized the transformative potential of their technologies. He stated, "Our technology can significantly enhance treatments for patients with stroke and lung fibrosis. With this funding, we will strengthen our position as the European market leader and extend our impact to the U.S. healthcare system."

Vision for the Future

The CEO's vision extends beyond just commercial growth; it encompasses a commitment to advancing patient care. Brainomix aims to leverage its innovative platform not only to improve treatment outcomes but also to democratize access to advanced healthcare technologies worldwide. The ongoing expansion of its global operations is a testament to its dedication to meeting critical healthcare needs.

John Pearson, Chief Investment Officer at Parkwalk, affirmed the potential of AI to revolutionize healthcare. He voiced excitement over supporting a company that addresses essential needs while demonstrating impressive growth. Meanwhile, Dr. Oliver Reuss from Boehringer Ingelheim highlighted Brainomix’s successful integration of AI solutions within clinical practice, reinforcing a shared vision to enhance patient care in lung disease.

Conclusion

As Brainomix continues its journey fueled by substantial investments, its commitment to utilizing AI technology promises to reshape the future of healthcare for stroke and lung fibrosis patients. With ambitious plans for expansion and innovation, the company represents a beacon of hope for improved patient outcomes in critical areas of medical science.

For more information on Brainomix and its impactful technologies, visit their official website or follow them on social media.